Severe Thrombocytopenia in Patients With Advanced Neuroendocrine Tumor Treated With Peptide Receptor Radioligand Therapy

Peptide receptor radioligand therapy (PRRT) was Food and Drug Administration approved in 2018 for the treatment of unresectable somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (NETs) and provides an important option for patients with advanced disease. A known adverse effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Naveed Ahmad, Junid A., Schroeder, Brett B., Ruhoy, Steven M., Kennecke, Hagen F., Lin, Bruce S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983945/
https://www.ncbi.nlm.nih.gov/pubmed/35307721
http://dx.doi.org/10.1097/RLU.0000000000004130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983945/
https://www.ncbi.nlm.nih.gov/pubmed/35307721
http://dx.doi.org/10.1097/RLU.0000000000004130

Ejemplares similares